| Name | Gla domain |
|---|---|
| Synonyms | Christmas factor; PTC; FIX; Coagulant factor IX; Coagulation factor IX; Coagulation factor IX precursor; F9; F9 protein… |
| Name | warfarin |
|---|---|
| CAS |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 18722586 | Safaoui MN, Aazami R, Hotz H, Wilson MT, Margulies DR: A promising new alternative for the rapid reversal of warfarin coagulopathy in traumatic intracranial hemorrhage. Am J Surg. 2009 Jun;197(6):785-90. Epub 2008 Aug 22. BACKGROUND: Internationally, Factor IX complex (FIX complex) has been used to correct warfarin-induced coagulopathy. |
81(1,1,1,1) | Details |
| 20004955 | Szlam F, Luan D, Bolliger D, Szlam AD, Levy JH, Varner JD, Tanaka KA: Anti-factor IXa Aptamer reduces propagation of thrombin generation in plasma anticoagulated with warfarin. Thromb Res. 2009 Dec 9. |
81(1,1,1,1) | Details |
| 19188667 | Souri M, Iwata H, Zhang WG, Ichinose A: Unique secretion mode of human protein Z: its Gla domain is responsible for inefficient, -dependent and warfarin-sensitive secretion. Blood. 2009 Apr 16;113(16):3857-64. Epub 2009 Feb 2. |
31(0,1,1,1) | Details |
| 18425569 | Umer Usman MH, Raza S, Raza S, Ezekowitz M: Advancement in antithrombotics for stroke prevention in atrial fibrillation. J Interv Card Electrophysiol. 2008 Aug;22(2):129-37. Epub 2008 Apr 17. The current standard of therapy includes warfarin, acenocoumarol and phenprocoumon which have proven efficacy by reducing stroke by 68% against placebo. Newer agents such as direct thrombin inhibitors, factor Xa inhibitors, factor IX inhibitors, tissue factor inhibitors and a novel antagonist are being developed to overcome the limitations of current agents. |
1(0,0,0,1) | Details |
| 18841275 | Vasse M: Protein Z, a protein seeking a pathology. Thromb Haemost. 2008 Oct;100(4):548-56. Protein Z (PZ) is a -dependent factor identified in human plasma in 1984 characterized by an homology with other -dependent factors (factor VII, IX, X, protein C). In humans, PZ is characterized by an unusual wide distribution in plasma, and a major decrease induced by warfarin. |
1(0,0,0,1) | Details |
| 18634396 | Sawicka-Powierza J, Rogowska-Szadkowska D, Oltarzewska AM, Chlabicz S: [Factors influencing activity of oral anticoagulants. Pol Merkur Lekarski. 2008 May;24(143):458-62. A mutation in the factor IX is responsible for the risk of bleeding during OAC therapy without excessive prolongation of the prothrombin time (PT). A common mutation in the gene coding for the cytochrome P450 (CYP2C9), with one or more combinations of its polymorphisms, is responsible for the reduced warfarin requirements or for the resistance to warfarin. |
1(0,0,0,1) | Details |